Clinical Trial

The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 28, 2025 (before its estimated January 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Autologous bone marrow-derived mesenchymal cells will be injected into patients diagnosed with premature ovarian failure
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-03-22.
Status change: Recruiting → Active, Not Recruiting 2025-01-23
Trial Details
NCT Number NCT04815213
Lead Sponsor University of Jordan
Conditions Premature Ovarian Failure
Enrollment 10 participants
Start Date 2022-01-01
Primary Completion 2025-01-31 (estimated)
Study Completion 2027-01-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-28